Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $293,450.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the transaction, the director now owns 33,611 shares in the company, valued at approximately $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Trading Up 2.4 %

Shares of NASDAQ HALO opened at $59.53 on Thursday. The company’s 50 day simple moving average is $54.96 and its 200 day simple moving average is $54.71. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market capitalization of $7.33 billion, a P/E ratio of 17.36, a P/E/G ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. On average, analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Benchmark reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently made changes to their positions in HALO. Vanguard Group Inc. grew its position in Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after purchasing an additional 386,618 shares in the last quarter. Snyder Capital Management L P lifted its stake in shares of Halozyme Therapeutics by 2.6% during the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock worth $199,294,000 after buying an additional 105,086 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Halozyme Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after buying an additional 30,901 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock worth $92,446,000 after buying an additional 47,795 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Halozyme Therapeutics by 8.7% during the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company’s stock worth $87,386,000 after buying an additional 145,617 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.